BridgeBio Oncology Therapeutics (BBOT) Competitors

BridgeBio Oncology Therapeutics logo
$1.81 -0.05 (-2.69%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.94 +0.14 (+7.46%)
As of 11/20/2026 05:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BBOT vs. AURA, DBVT, PRME, JANX, and NVCT

Should you buy BridgeBio Oncology Therapeutics stock or one of its competitors? BridgeBio Oncology Therapeutics's main competitors and comparable companies include Aura Biosciences (AURA), DBV Technologies (DBVT), Prime Medicine (PRME), Janux Therapeutics (JANX), and Nuvectis Pharma (NVCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BridgeBio Oncology Therapeutics compare to Aura Biosciences?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Aura Biosciences (NASDAQ:AURA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

Aura Biosciences is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Oncology TherapeuticsN/AN/A-$134.04M-$2.16N/A
Aura BiosciencesN/AN/A-$106.19M-$1.64N/A

In the previous week, Aura Biosciences had 2 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 5 mentions for Aura Biosciences and 3 mentions for BridgeBio Oncology Therapeutics. Aura Biosciences' average media sentiment score of -0.28 beat BridgeBio Oncology Therapeutics' score of -0.28 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BridgeBio Oncology Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aura Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral

BridgeBio Oncology Therapeutics has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market.

BridgeBio Oncology Therapeutics currently has a consensus target price of $19.33, indicating a potential upside of 968.14%. Aura Biosciences has a consensus target price of $17.50, indicating a potential upside of 154.73%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than Aura Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BridgeBio Oncology Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82
Aura Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are owned by insiders. Comparatively, 1.9% of Aura Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

BridgeBio Oncology Therapeutics' return on equity of -49.01% beat Aura Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
BridgeBio Oncology TherapeuticsN/A -49.01% -43.18%
Aura Biosciences N/A -64.68%-56.08%

Summary

BridgeBio Oncology Therapeutics beats Aura Biosciences on 7 of the 12 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to DBV Technologies?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and DBV Technologies (NASDAQ:DBVT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

BridgeBio Oncology Therapeutics has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.84, meaning that its stock price is 184% less volatile than the broader market.

In the previous week, BridgeBio Oncology Therapeutics had 1 more articles in the media than DBV Technologies. MarketBeat recorded 3 mentions for BridgeBio Oncology Therapeutics and 2 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 0.34 beat BridgeBio Oncology Therapeutics' score of -0.28 indicating that DBV Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BridgeBio Oncology Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
DBV Technologies
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are owned by insiders. Comparatively, 1.1% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

BridgeBio Oncology Therapeutics presently has a consensus price target of $19.33, indicating a potential upside of 968.14%. DBV Technologies has a consensus price target of $45.25, indicating a potential upside of 401.11%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than DBV Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BridgeBio Oncology Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82
DBV Technologies
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

BridgeBio Oncology Therapeutics has a net margin of 0.00% compared to DBV Technologies' net margin of -5,392.17%. BridgeBio Oncology Therapeutics' return on equity of -49.01% beat DBV Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
BridgeBio Oncology TherapeuticsN/A -49.01% -43.18%
DBV Technologies -5,392.17%-120.95%-88.35%

BridgeBio Oncology Therapeutics has higher earnings, but lower revenue than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Oncology TherapeuticsN/AN/A-$134.04M-$2.16N/A
DBV Technologies$5.64M100.67-$146.95M-$3.01N/A

Summary

BridgeBio Oncology Therapeutics beats DBV Technologies on 11 of the 14 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

BridgeBio Oncology Therapeutics has a net margin of 0.00% compared to Prime Medicine's net margin of -2,497.56%. BridgeBio Oncology Therapeutics' return on equity of -49.01% beat Prime Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Prime Medicine-2,497.56% -222.88% -59.68%
BridgeBio Oncology Therapeutics N/A -49.01%-43.18%

Prime Medicine has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

In the previous week, Prime Medicine had 14 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 17 mentions for Prime Medicine and 3 mentions for BridgeBio Oncology Therapeutics. Prime Medicine's average media sentiment score of 0.72 beat BridgeBio Oncology Therapeutics' score of -0.28 indicating that Prime Medicine is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Prime Medicine
2 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BridgeBio Oncology Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

BridgeBio Oncology Therapeutics has lower revenue, but higher earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prime Medicine$4.63M139.49-$201.14M-$0.96N/A
BridgeBio Oncology TherapeuticsN/AN/A-$134.04M-$2.16N/A

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. 16.0% of Prime Medicine shares are owned by insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Prime Medicine currently has a consensus target price of $7.86, suggesting a potential upside of 121.33%. BridgeBio Oncology Therapeutics has a consensus target price of $19.33, suggesting a potential upside of 968.14%. Given BridgeBio Oncology Therapeutics' higher possible upside, analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than Prime Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prime Medicine
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.89
BridgeBio Oncology Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82

Summary

Prime Medicine beats BridgeBio Oncology Therapeutics on 8 of the 15 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

In the previous week, Janux Therapeutics had 9 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 12 mentions for Janux Therapeutics and 3 mentions for BridgeBio Oncology Therapeutics. Janux Therapeutics' average media sentiment score of 0.35 beat BridgeBio Oncology Therapeutics' score of -0.28 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Janux Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
BridgeBio Oncology Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Janux Therapeutics has higher revenue and earnings than BridgeBio Oncology Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Janux Therapeutics$10M61.67-$113.62M-$1.59N/A
BridgeBio Oncology TherapeuticsN/AN/A-$134.04M-$2.16N/A

Janux Therapeutics presently has a consensus price target of $36.92, indicating a potential upside of 266.30%. BridgeBio Oncology Therapeutics has a consensus price target of $19.33, indicating a potential upside of 968.14%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than Janux Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Janux Therapeutics
2 Sell rating(s)
3 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.63
BridgeBio Oncology Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by company insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Janux Therapeutics' return on equity of -11.80% beat BridgeBio Oncology Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Janux TherapeuticsN/A -11.80% -10.97%
BridgeBio Oncology Therapeutics N/A -49.01%-43.18%

Janux Therapeutics has a beta of 2.44, suggesting that its share price is 144% more volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

Summary

Janux Therapeutics beats BridgeBio Oncology Therapeutics on 10 of the 13 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Nuvectis Pharma?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

In the previous week, BridgeBio Oncology Therapeutics had 1 more articles in the media than Nuvectis Pharma. MarketBeat recorded 3 mentions for BridgeBio Oncology Therapeutics and 2 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 1.35 beat BridgeBio Oncology Therapeutics' score of -0.28 indicating that Nuvectis Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BridgeBio Oncology Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Nuvectis Pharma
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are owned by insiders. Comparatively, 28.6% of Nuvectis Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

BridgeBio Oncology Therapeutics' return on equity of -49.01% beat Nuvectis Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
BridgeBio Oncology TherapeuticsN/A -49.01% -43.18%
Nuvectis Pharma N/A -119.87%-91.60%

BridgeBio Oncology Therapeutics presently has a consensus price target of $19.33, suggesting a potential upside of 968.14%. Nuvectis Pharma has a consensus price target of $36.25, suggesting a potential upside of 86.95%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe BridgeBio Oncology Therapeutics is more favorable than Nuvectis Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BridgeBio Oncology Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82
Nuvectis Pharma
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.50

Nuvectis Pharma is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Oncology TherapeuticsN/AN/A-$134.04M-$2.16N/A
Nuvectis PharmaN/AN/A-$26.44M-$1.89N/A

BridgeBio Oncology Therapeutics has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.21, indicating that its share price is 121% less volatile than the broader market.

Summary

BridgeBio Oncology Therapeutics beats Nuvectis Pharma on 7 of the 13 factors compared between the two stocks.

Get BridgeBio Oncology Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BBOT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BBOT vs. The Competition

MetricBridgeBio Oncology TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$158.90M$4.07B$7.78B$11.72B
Dividend YieldN/A3.63%2.47%4.72%
P/E RatioN/A27.1833.1628.09
Price / SalesN/A15.278.105.42
Price / CashN/A22.9521.0121.90
Price / Book0.494.004.263.50
Net Income-$134.04M-$24.03M$3.50B$394.12M
1 Month Performance-32.46%-13.38%-10.48%-12.15%
1 Year PerformanceN/A-7.85%-4.61%-11.41%

BridgeBio Oncology Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BBOT
BridgeBio Oncology Therapeutics
3.544 of 5 stars
$1.81
-2.7%
$19.33
+968.1%
N/A$158.90MN/AN/A88
AURA
Aura Biosciences
1.7923 of 5 stars
$7.11
flat
$17.50
+146.1%
+28.4%$739.97MN/AN/A113
DBVT
DBV Technologies
3.4398 of 5 stars
$11.02
-3.6%
$45.25
+310.6%
-34.4%$718.69M$5.64MN/A125
PRME
Prime Medicine
3.5299 of 5 stars
$4.27
+9.8%
$7.86
+84.0%
-3.8%$705.56M$4.63MN/A146
JANX
Janux Therapeutics
2.6647 of 5 stars
$11.37
-1.0%
$36.92
+224.7%
-64.7%$703.30M$10MN/A114

Related Companies and Tools


This page (NASDAQ:BBOT) was last updated on 11/21/2026 by MarketBeat.com Staff.
From Our Partners